-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Neuropsychiatric symptoms (NPS) are very common in the cognitive function spectrum of the elderly.
In the development of cognitive ability, it affects half of patients with mild cognitive impairment and almost all patients with dementia
.
Neuropsychiatric symptoms have predictive value in predicting accelerated disease progression and functional decline
Neuropsychiatric symptoms (NPS) are very common in the cognitive function spectrum of the elderly.
According to reports, up to 72% of Alzheimer's (AD) patients are indifferent
JAMA
This multicenter randomized placebo-controlled clinical trial was conducted in 10 multicenter specialty clinics from August 2016 to July 2020
.
A total of 307 potential participants were screened
The results showed that of the 200 participants, 99 were assigned to methylphenidate and 101 were assigned to placebo
.
The median (quartile) age of the study participants was 76 (71-81) years; 68 (34%) were women, and 131 (66%) were men
Compared with placebo, patients treated with methylphenidate had a greater decrease in the NPI apathy score from baseline to 6 months (mean -1.
NPI score difference between the two groups during follow-up
Among them, in the first 100 days, the NPI apathy score decreased the most.
Compared with placebo, the apathy symptoms of the participants who received methylphenidate improved more than doubled (HR=2.
16; 95%CI, 1.
19-3.
91)
.
At 6 months, compared with placebo, the probability of an improvement in the AD impression score of methylphenidate was 1.
Among them, in the first 100 days, the NPI apathy score decreased the most.
In summary, methylphenidate is a safe and effective drug, which can significantly improve the indifferent symptoms of Alzheimer's disease
references:
Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease: The ADMET 2 Randomized Clinical Trial.
Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease: The ADMET 2 Randomized Clinical Trial.
Leave a message here
